EC Number |
Application |
Reference |
---|
3.1.1.47 | diagnostics |
potential role of PAF-AH and PON1 as prognostic markers of the leptospirosis outcome |
713682 |
3.1.1.47 | diagnostics |
the enzyme is a positive risk factor for coronary disease and measurements of its amount may contribute to the prediction of coronary heart disease risk, especially in individuals with low LDL cholesterol levels |
650932 |
3.1.1.47 | diagnostics |
the plasma enzyme is an important risk marker for endothelial dysfunction in patients with non-insulin dependent diabetes mellitus |
652609 |
3.1.1.47 | diagnostics |
the ratio of the HDL-associated enzyme to total plasma enzyme activity is a useful marker for atherogenicity in subjects with primary hypercholesterolemia |
652705 |
3.1.1.47 | medicine |
an altered location of PAF-AH correlates with diseases such as coronary artery disease, hypercholesterolemia, paroxysmal atrial fibrillation and chronic kidney disease |
693071 |
3.1.1.47 | medicine |
elevated Lp-PLA2 levels are correlated to increased risk for cardiovascular events |
690322 |
3.1.1.47 | medicine |
in human neither in asthma nor in sepsis the recombinant enzyme shows sufficient efficiacy. In numerous animal models of inflammation or sepsis rPAF-AH is efficient, pointing out the extreme difficulty to extrapolate from small animal models to human beings |
678390 |
3.1.1.47 | medicine |
lipoprotein associated phospholipase A2 is a cardiovascular risk marker, in addition, its inhibition reduces the generation of oxidized fatty acids |
691653 |
3.1.1.47 | medicine |
lipoprotein-associated phospholipase A2 is a biomarker that can be used to assess the risk for cardiovascular disease and events, in addition several studies suggest that the enzyme has a pathological role in the atherosclerotic disease process |
691929 |
3.1.1.47 | medicine |
lipoprotein-associated phospholipase A2 is among the multiple cardiovascular biomarkers that have been associated with increased cardiovascular disease risk |
690321 |